摘要
社区获得性肺炎(CAP)是亚洲成人病死的主要原因之一。近年来,尽管诊断技术在不断进步,新型抗菌药物陆续上市,但CAP的发病率和病死率仍然较高。不同研究中CAP病原菌分布各有不同,耐药情况也有所差异。本文对社区获得性肺炎的病原学及耐药现状进行综述,为临床治疗提供参考。
Community-acquired pneumonia(CAP) is a major cause of adult mortality in Asia. In recent years, despite the continuous advancement in diagnostic technology and the successive listing of new antibiotics, the incidence and mortality of CAP are still relatively high. In different studies, the distribution of pathogenic bacteria in CAP and the drug resistance varies. This article reviews the etiology and drug resistance of community-acquired pneumonia, and provides reference for clinical treatment.
作者
胡月
王宇
刘景院
张福杰
Hu Yue;Wang Yu;Liu Jingyuan;Zhang Fujie(Clinical and Research Center of Infectious Diseases;Pneumology Department;Department of Critical Care Medicine,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China)
出处
《中华实验和临床感染病杂志(电子版)》
CAS
2018年第3期209-211,共3页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
基金
北京市科学技术委员会基金(No.D161100000416003)
关键词
病原学
耐药
社区获得性
肺炎
Aetiology
Antibiotic resistance
Community-acquired
Pneumonia